Join us on the official University of Michigan Rose Bowl Tour!

First Gene Therapy for Adults with Hemophilia B Sustains Safety and Efficacy

March 6, 2023


Read time:

<5 mins
Blood Vial
Presented by Health Lab

According to new data from a Michigan Medicine-led trial, the first and only approved gene therapy for adults with bleeding disorder hemophilia B remained safe and effective two years after treatment. Steven Pipe, M.D., professor of pediatrics and pathology at the U-M Medical School Hospital, discusses this transformative and clinical trial.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.